Description

Capmatinib Hydrochloride is a potent and selective small-molecule inhibitor of the mesenchymal-epithelial transition (MET) receptor tyrosine kinase. This targeted therapeutic agent is critical for advanced pharmaceutical research and development, particularly in oncology. It is primarily utilized by pharmaceutical companies, contract research organizations (CROs), and academic research institutions focused on developing novel cancer treatments, especially for non-small cell lung cancer (NSCLC) and other MET-dysregulated tumors.

Application

• Pharmaceutical Active Ingredient (API): Serves as the core active component in the formulation of targeted cancer therapeutics.
• Oncology Research: Used as a critical reference standard and biochemical tool in preclinical studies to investigate MET signaling pathways and tumor biology.
• Drug Development: Essential for formulation studies, stability testing, and the development of dosage forms such as tablets or capsules in clinical trial material (CTM) manufacturing.
• Biochemical Assays: Employed in high-throughput screening (HTS) and enzyme inhibition assays to evaluate potency and selectivity.
• Metabolism and Pharmacokinetics (DMPK) Studies: Used in ADME (Absorption, Distribution, Metabolism, Excretion) studies to understand the drug's behavior in biological systems.
• Quality Control & Analytical Testing: Functions as a certified reference material (CRM) for HPLC, LC-MS, and other analytical methods to ensure product quality and regulatory compliance.

Basic Information

Product Name	Capmatinib Hydrochloride
CAS No.	1865733-40-9
Molecular Formula	C23H17FN6O • HCl
Molecular Weight	463.88 g/mol (free base: 424.42 g/mol)
Synonyms	Capmatinib HCl; INC280 hydrochloride; N-[(4-{[2-(Difluoromethoxy)phenyl]carbamoyl}-5-methyl-1H-imidazol-2-yl)methyl]-1-methyl-1H-1,2,3-triazole-4-carboxamide hydrochloride; INCB028060 hydrochloride; 1-Methyl-N-[(5-methyl-4-{[2-(difluoromethoxy)phenyl]carbamoyl}-1H-imidazol-2-yl)methyl]-1H-1,2,3-triazole-4-carboxamide hydrochloride
EINECS	Contact for details

Quality Control

Our Capmatinib Hydrochloride is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, and strength conform to high-grade pharmaceutical standards. A comprehensive Certificate of Analysis (COA) is provided with each shipment, detailing results for assay, related substances, residual solvents, and other critical parameters. We support compliance with cGMP, ICH Q7, and other relevant regulatory guidelines for active pharmaceutical ingredients (APIs).

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under inert conditions or in a desiccator to maintain stability and potency. For long-term storage, consider freezing at -20°C.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0% (on anhydrous basis)
Related Substances (HPLC)	Total impurities ≤2.0% Any single unknown impurity ≤0.5%
Water Content (KF)	≤1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.